How should an asymptomatic patient with a left ventricular ejection fraction of 40–45% be managed?

Management of Asymptomatic LVEF 40–45%

Initiate comprehensive four-pillar guideline-directed medical therapy (GDMT) immediately—ARNI/ACE-inhibitor, beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor—because this ejection fraction falls within the HFmrEF category (41–49%) and shares the clinical profile, prognosis, and therapeutic responsiveness of HFrEF, with proven mortality reduction from early neurohormonal blockade even in asymptomatic patients. 1, 2

Classification and Diagnostic Confirmation

• Your patient's LVEF of 40–45% places them in the heart failure with mildly reduced ejection fraction (HFmrEF) category, defined as LVEF 41–49%. 1, 2

• Obtain a second confirmatory echocardiogram before committing to long-term therapy, because LVEF measurements can vary by 5–10% due to imaging technique, reader interpretation, and clinical status; a single measurement should never dictate definitive therapeutic decisions. 3, 1

• Measure BNP or NT-proBNP to confirm the diagnosis and stratify prognosis; markedly elevated natriuretic peptides provide diagnostic certainty and are required for HFmrEF diagnosis alongside structural cardiac abnormalities (elevated filling pressures, left atrial enlargement, or increased LV mass). 1, 2

• Assign NYHA functional class based on any exertional symptoms, even if the patient reports being "asymptomatic"—subtle dyspnea on exertion or fatigue may be present but dismissed by the patient. 1

Immediate Pharmacologic Therapy (Four-Pillar GDMT)

First Pillar: RAAS Inhibition

• Start sacubitril/valsartan (ARNI) as first-line RAAS blockade, titrating from 24/26 mg twice daily to target dose of 97/103 mg twice daily over 3–6 weeks; it provides superior reductions in cardiovascular mortality and heart failure hospitalization compared with ACE-inhibitors or ARBs. 1

• If sacubitril/valsartan is unavailable or unaffordable, substitute an ACE-inhibitor (enalapril 2.5–10 mg twice daily, lisinopril 5–40 mg daily, or ramipril 2.5–10 mg daily) and titrate to maximally tolerated doses. 1, 4

• Monitor blood pressure, serum creatinine, and potassium at 1–2 weeks after initiation and after each dose escalation to detect hypotension, acute kidney injury, or hyperkalemia. 1

Second Pillar: Beta-Blocker

• Initiate a guideline-recommended beta-blocker concurrently (carvedilol 3.125–25 mg twice daily, metoprolol succinate 12.5–200 mg daily, or bisoprolol 1.25–10 mg daily), targeting a resting heart rate of 50–60 bpm or the highest tolerated dose. 1, 4

• Beta-blockers reduce mortality in all patients with LVEF ≤40% irrespective of symptom status, and HFmrEF patients derive similar benefit to HFrEF. 1, 2

Third Pillar: Mineralocorticoid Receptor Antagonist

• Add spironolactone 12.5–25 mg daily or eplerenone 25–50 mg daily if the confirmed LVEF remains ≤35% on repeat imaging, provided eGFR ≥30 mL/min/1.73 m² and serum potassium ≤5.0 mmol/L. 1

• If LVEF is confirmed at 36–45%, MRA remains reasonable given the continuous nature of ejection fraction and the intermediate risk profile of HFmrEF. 1, 2

• Check potassium and creatinine at 3 days, 1 week, then monthly for three months after MRA initiation to detect life-threatening hyperkalemia. 1

Fourth Pillar: SGLT2 Inhibitor

• Prescribe dapagliflozin 10 mg daily or empagliflozin 10 mg daily regardless of diabetes status, because SGLT2 inhibitors lower cardiovascular mortality, all-cause mortality, and heart failure hospitalization across the entire spectrum of reduced and mildly reduced ejection fraction. 1, 2

Device Therapy Considerations

• Do not implant an ICD for primary prevention at this LVEF, because current guidelines require LVEF ≤35% for Class I indication in asymptomatic patients. 3, 1

• Reassess LVEF in 3–6 months after optimizing GDMT; if it remains ≤35% despite maximal medical therapy and the patient is ≥40 days post-myocardial infarction (if ischemic etiology) with expected survival >1 year, ICD implantation becomes a Class I indication. 1

• Cardiac resynchronization therapy (CRT) is not indicated unless LVEF falls to ≤35%, the patient develops NYHA class II–IV symptoms, and has left bundle branch block with QRS ≥150 ms. 1

Monitoring and Follow-Up

• Schedule outpatient visits every 3 months initially to assess medication tolerance, symptom trajectory, blood pressure, heart rate, renal function, and electrolytes. 1

• Repeat transthoracic echocardiography in 6 months to determine whether LVEF has improved (HFimpEF, LVEF >40%), remained stable, or deteriorated to HFrEF (LVEF ≤40%). 1, 2

• Continue all four GDMT pillars even if LVEF improves above 40%, because abrupt discontinuation leads to relapse of heart failure and recurrent left ventricular dysfunction. 1

• Measure BNP or NT-proBNP at each visit to track disease trajectory; rising values predict decompensation even before symptoms emerge. 1

Etiology-Specific Interventions

• Assess for residual coronary ischemia or incomplete revascularization if the patient has prior coronary stents; stress testing or coronary angiography is warranted because additional revascularization—preferably CABG over PCI in multivessel disease with LVEF ≤35%—improves long-term survival. 1

• Screen for significant valvular disease (especially mitral regurgitation, which can cause dyspnea and volume overload even with preserved LVEF) and thyroid dysfunction, as their identification may alter management. 1, 5

• If the underlying etiology remains uncertain, obtain cardiac MRI for tissue characterization; the results influence eligibility for ICD therapy and may reveal infiltrative or inflammatory cardiomyopathy requiring specific treatment. 1

Critical Pitfalls to Avoid

• Do not delay GDMT initiation awaiting symptom development; early neurohormonal blockade prevents progression to overt heart failure and reduces mortality even in asymptomatic patients. 1, 4

• Do not rely on a single LVEF measurement for definitive therapeutic decisions; repeat imaging is mandatory to account for measurement variability. 3, 1

• Do not prescribe MRA when eGFR <30 mL/min/1.73 m² or potassium >5.0 mmol/L, due to risk of life-threatening hyperkalemia. 1

• Do not withhold beta-blockers if mild volume overload develops; instead optimize diuretic therapy while continuing beta-blockade. 1

• Do not discontinue GDMT if LVEF improves above 40%; maintain all four pillars indefinitely to prevent relapse. 1

• Do not assume "asymptomatic" means no intervention is needed; HFmrEF carries substantial risk of cardiovascular events, and early treatment alters the natural history. 6, 2, 7